Market closedNon-fractionalADR
Evotec/EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Ticker
EVO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Hamburg, Germany
Employees
-
Website
www.evotec.com
Evotec Metrics
BasicAdvanced
$1.7B
Market cap
-
P/E ratio
-
EPS
1.47
Beta
-
Dividend rate
Price and volume
Market cap
$1.7B
Beta
1.47
52-week high
$13.49
52-week low
$4.50
Average daily volume
2.9
Financial strength
Management effectiveness
Valuation
Growth
What the Analysts think about Evotec
Analyst Ratings
Majority rating from 5 analysts.
Evotec Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.04
-$0.12
-$0.05
-$0.07
-
Expected
-$0.04
-$0.05
-$0.03
-$0.10
-$0.06
Surprise
10.94%
149.25%
49.55%
-35.84%
-
Evotec News
AllArticlesVideos
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Accesswire·2 weeks ago
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Accesswire·3 weeks ago
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.7B as of July 27, 2024.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of July 27, 2024.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Evotec stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.